Perplexity just launched Premium Health Sources, pulling clinical data directly from paywalled references like the New England Journal of Medicine, BMJ Journals, and BMJ Best Practice. In Computer mode, relevant questions automatically trigger these professional databases with direct citations, replacing generic web summaries with peer-reviewed medical evidence.
OpenAI's o1 model just outperformed two attending physicians in diagnosing 76 real emergency room cases, according to a new Harvard study published in Science. Tested directly on raw electronic medical records, o1 nailed the diagnosis 67% of the time during triage, topping the doctors' 55% and 50% marks. While critics noted the test used internists instead of ER specialists, researchers say prospective trials in real care settings are urgently needed.
Neuralink just revealed a custom five-axis surgical robot designed to automate brain-computer interface implants. Armed with eight cameras and real-time OCT scanners, the machine threads hair-thin electrodes directly through the dura mater without cutting it away. It paves the way for high-precision, scaled operations, though human surgeons still handle the initial craniectomy.
Mayo Clinic just unveiled an AI model that can spot pancreatic cancer on routine abdominal CT scans up to three years before clinical diagnosis. Published in Gut, the system catches subtle signs before tumors are visible, buying critical time for curative treatment against one of the deadliest cancers.
OpenAI just launched ChatGPT for Clinicians, making a specialized version of its chatbot free for verified U.S. healthcare providers like physicians and pharmacists. Built with hundreds of physician advisors, it streamlines clinical notes, conducts deep literature reviews with peer-reviewed citations, and tracks CME credits. Testers rated 99.6% of responses safe and accurate, marking a major step toward embedding frontier AI into everyday patient care.
Northwestern University engineers just developed flexible printed artificial neurons that directly communicate with and activate living brain cells in mouse tissue. Printed using nanomaterial inks, the low-cost devices generate complex, lifelike electrical signals. Why it matters: This could advance neural implants for restoring sensory functions while inspiring ultra-efficient neuromorphic hardware that slashes AI's surging energy demands.
OpenAI just unveiled GPT-Rosalind, a frontier reasoning model purpose-built for biology, genomics, and drug discovery. It beats GPT-5.4 on six of 11 LABBench2 tasks and landed in the 95th percentile against human experts on RNA sequence prediction. While model access requires trusted vetting, OpenAI also dropped a free research plugin on GitHub.
AWS just rolled out Amazon Bio Discovery, a no-code agentic platform that puts 40+ biological AI models and wet-lab validation under one roof. Instead of juggling custom pipelines and manual handoffs, teams can pick models via AI agents, order lab assays from partners like Ginkgo Bioworks, and feed results right back into the loop. In tests with MSK, it sifted 300,000 antibody candidates in weeks instead of a full year.
OpenAI just partnered with pharma giant Novo Nordisk to embed its frontier models across the company's entire workflow, from lab drug discovery to global distribution. Novo Nordisk aims to simulate lab experiments and crunch complex biological datasets to slash chronic disease drug timelines, while OpenAI trains staff to build custom tools under human oversight.
A two-person telehealth startup called Medvi is on track for a staggering $1.8B sales run rate, operating out of a Los Angeles living room with a stack of off-the-shelf AI tools. Founder Matthew Gallagher uses ChatGPT, Claude, Midjourney, and ElevenLabs to run code, marketing, and support while outsourcing medical and shipping logistics. Why it matters: It is the clearest validation yet of the "one-person unicorn" prediction, showing that using AI for leverage can rival companies with thousands of employees.
Researchers just published ProtAIDe-Dx in Nature Medicine, a deep joint-learning model that detects six dementia-linked conditions simultaneously using blood plasma proteomics. Trained on data from 17,187 individuals, the AI hit 70% to 95% balanced classification accuracy across all conditions while identifying complex co-pathologies. Why it matters: Clinical dementia misdiagnosis rates currently run between 25% and 50%, and a routine blood test could dramatically accelerate accurate, early intervention.
Anthropic just signed an AI safety agreement with the Australian government to share frontier model evaluations and economic data. Alongside the pact, the company committed AUD$3 million in Claude API credits to four local research institutions for rare disease diagnosis and genomics, while prepping a new Sydney office.
California biotech startup R3 Bio has been pitching investors on growing nonsentient, "brainless" human clones to serve as living backup bodies and custom organ sources. While the company publicly claims it only raised funds to create monkey "organ sacks" for lab testing, confidential presentations revealed far more radical anti-aging ambitions. Ethicists warn the concept crosses terrifying lines, even as longevity backers pour money into body replacement.
Anthropic is reportedly testing a dedicated desktop mode called Operon built specifically for computational biology. It can access local research files to design CRISPR screens, analyze single-cell RNA data, and run automated research workflows. The workspace is still in early testing, but it marks Anthropic's deepest move yet into life sciences.
Meta just introduced TRIBE v2, a foundation model that predicts how the human brain responds to sights, sounds, and language. Trained on fMRI data from over 700 volunteers, it enables zero-shot predictions for new subjects and tasks, letting neuroscientists test brain hypotheses without recruiting human subjects for every test.
OpenAI Foundation just announced it will invest at least $1 billion over the next year across life sciences, economic impact, AI resilience, and community initiatives. Led in part by co-founder Wojciech Zaremba, early focus areas include Alzheimer's research, biosecurity, and child safety safeguards. Why it matters: OpenAI is putting serious capital behind mitigating the societal shocks and advancing the medical upsides of frontier AI.
Perplexity just launched Perplexity Health, a new feature linking electronic medical records from 1.7 million providers with wearables like Apple Health and Fitbit. Instead of generic web results, answers combine your clinical history and lab work with peer-reviewed medical citations. Health data is encrypted and won't train models, rolling out first to U.S. Pro and Max users.
An Australian tech founder used ChatGPT and AlphaFold to analyze his dog's tumor DNA and target mutated proteins, teaming up with UNSW researchers to develop a bespoke mRNA vaccine in two months. Rosie's tumors have dramatically shrunk, showing how AI can rapidly accelerate and democratize personalized cancer therapeutics.
Researchers at UMass Amherst just built an artificial neuron operating at biological voltage near 0.1 volts, cutting power consumption by 100x compared to earlier designs. Driven by bacterial protein nanowires, it successfully held real-time electrical conversations with living cells. Why it matters: Matching biology's native voltage could let future neural implants ditch bulky signal amplifiers.
Microsoft just launched Copilot Health, a secure personal health hub within Copilot that aggregates records from over 50,000 U.S. hospitals and data from 50+ wearables like Apple Health and Fitbit. It delivers actionable wellness insights and helps prep doctor visits without replacing physicians, keeping data isolated and out of AI training pools. A waitlist is now open for U.S. adults.
